

of drafts of regulations or guidelines or similar preexisting internal agency documents, but only if their premature disclosure is likely to significantly frustrate implementation of proposed agency action; review of trade secrets and confidential commercial or financial information submitted to the agency; consideration of matters involving investigatory files compiled for law enforcement purposes; and review of matters, such as personnel records or individual patient records, where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Examples of portions of FDA advisory committee meetings that ordinarily shall not be closed include the review, discussion, and evaluation of general preclinical and clinical test protocols and procedures for a class of drugs or devices; consideration of labeling requirements for a class of marketed drugs or devices; review of data and information on specific investigational or marketed drugs and devices that have previously been made public; presentation of any other data or information that is not exempt from public disclosure pursuant to the FACA, as amended; and, deliberation to formulate advice and recommendations to the agency on matters that do not independently justify closing.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: March 9, 1995.

Linda A. Suydam,

Interim Deputy Commissioner for Operations.
[FR Doc. 95-6427 Filed 3-15-95; 8:45 am]

BILLING CODE 4160-01-F

Office of the Secretary

Correction of Notice of Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Correction.

SUMMARY: A Notice beginning on page 10588 in the issue of February 27, 1995, entitled "Findings of Scientific Misconduct" is hereby reprinted in its entirety because of an omission in the original printing:

Vivian N. Tanner, Cleveland Clinic Foundation: The Division of Research Investigations of the Office of Research Integrity (ORI) conducted an investigation into possible scientific misconduct on the part of Vivian N. Tanner while she was a clinic coordinator for the Collaborative Ocular

Melanoma Study (COMS) at the Cleveland Clinic Foundation (CCF). ORI concluded that Ms. Tanner committed scientific misconduct by falsifying and fabricating clinical trial data on research data forms related to a multicenter study on the treatment of choroidal melanoma, a rare form of eye cancer. Due to these falsifications and fabrications, inaccurate clinical data were entered into the clinical trial database. These acts were committed over a period of several years, were material, and, therefore, were potentially detrimental to the study. The CCF COMS project has received U.S. Public Health Service support from 1985 to the present through subcontract funds from a National Eye Institute cooperative agreement award to the COMS Coordinating Center, The Wilmer Ophthalmological Institute, The Johns Hopkins Medical Institutions, Baltimore, Maryland. Ms. Tanner has been debarred from eligibility for and involvement in grants as well as other assistance awards and contracts from the Federal Government for a period of three years. Because the COMS is an ongoing study, no publications were affected by the falsified or fabricated data, and no clinical treatment has been based on the results of the study.

FOR FURTHER INFORMATION, CONTACT:
Director, Division of Research Investigations, Office of Research Integrity, 301-443-5330.

Lyle W. Bivens, Ph.D.,

Director, Office of Research Integrity.

[FR Doc. 95-6446 Filed 3-15-95; 8:45 am]

BILLING CODE 4160-17-P

National Institutes of Health

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Chemistry and Related Sciences.

Date: March 27, 1995.

Time: 2:00 p.m.

Place: NIH, Westwood Building, Room 320, Telephone Conference.

Contact Person: Dr. Zakir Bengali, Scientific Review Administrator, 5333 Westbard Ave., Room 320, Bethesda, MD 20892, (301) 594-7317.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 3, 1995.

Time: 10:00 a.m.

Place: NIH, Westwood Building, Room 407B, Telephone Conference.

Contact Person: Dr. Betty Hayden, Scientific Review Administrator, 5333 Westbard Ave., Room 407B, Bethesda, MD 20892, (301) 594-7310.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 3, 1995.

Time: 3:00 p.m.

Place: NIH, Westwood Building, Room 407B, Telephone Conference.

Contact Person: Dr. Betty Hayden, Scientific Review Administrator, 5333 Westbard Ave., Room 407B, Bethesda, MD 20892, (301) 594-7310.

Name of SEP: Behavioral and Neurosciences.

Date: April 3, 1995.

Time: 8:30 a.m.

Place: Holiday Inn, Chevy Chase, MD.

Contact Person: Dr. Teresa Levitin, Scientific Review Admin., 5333 Westbard Ave., Room 303, Bethesda, MD 20894, (301) 594-7141.

Name of SEP: Chemistry and Related Sciences.

Date: April 4, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room 435, Telephone Conference.

Contact Person: Dr. Marcelina Powers, Scientific Review Administrator, 5333 Westbard Ave., Room 435, Bethesda, MD 20892, (301) 594-7120.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 4, 1995.

Time: 3:00 p.m.

Place: NIH, Westwood Building, Room 407B, Telephone Conference.

Contact Person: Dr. Betty Hayden, Scientific Review Administrator, 5333 Westbard Ave., Room 407B, Bethesda, MD 20892, (301) 594-7310.

Name of SEP: Chemistry and Related Sciences.

Date: April 6, 1995.

Time: 1:30 p.m.

Place: NIH, Westwood Building, Room 339B, Telephone Conference.

Contact Person: Dr. Jerry Critz, Scientific Review Administrator, 5333 Westbard Ave., Room 339B, Bethesda, MD 20892, (301) 594-7322.

Name of SEP: Microbiological and Immunological Sciences.

Date: April 7, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room 403C, Telephone Conference.

Contact Person: Dr. Anita Weinblatt, Scientific Review Admin., 5333 Westbard Ave., Room 403C, Bethesda, MD 20892, (301) 594-7175.

Name of SEP: Chemistry and Related Sciences.

Date: April 12, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room 435, Telephone Conference.

Contact Person: Dr. Marcelina Powers, Scientific Review Administrator, 5333 Westbard Ave., Room 435, Bethesda, MD 20892, (301) 594-7120.

Name of SEP: Clinical Sciences.

Date: May 2, 1995.

Time: 2:30 p.m.

Place: NIH, Westwood Building, Room 439, Telephone Conference.

Contact Person: Dr. Gordon Johnson, Scientific Review Admin., 5333 Westbard Ave., Room 439, Bethesda, MD 20892, (301) 594-7216.

The meetings will be closed in accordance with the provisions set forth in secs. 552(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.939-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 9, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, NIH.

[FR Doc. 95-6399 Filed 3-15-95; 8:45 am]

BILLING CODE 4140-01-M

Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

Purpose/Agenda: To review individual grant applications.

Name of SEP: Behavioral and Neurosciences.

Date: March 21, 1995.

Time: 2:00 p.m.

Place: NIH, Westwood Building, Room 319C, Telephone Conference.

Contact Person: Dr. Carl Banner, Scientific Review Administrator, 5333 Westbard Ave., Room 319A, Bethesda, MD 20892, (301) 594-7206.

Name of SEP: Behavioral and Neurosciences.

Date: April 3, 1995.

Time: 2:00 p.m.

Place: NIH, Westwood Building, Room 319C, Telephone Conference.

Contact Person: Dr. Anita Sostek, Scientific Review Administrator, 5333 Westbard Ave., Room 319C, Bethesda, MD 20892, (301) 594-7358.

Name of SEP: Behavioral and Neurosciences.

Date: April 20, 1995.

Time: 8:00 a.m.

Place: Bethesda Marriott, Bethesda, MD.

Contact Person: Dr. Leonard Jakubczak, Scientific Review Admin., 5333 Westbard Ave., Room 325C, Bethesda, MD 20892, (301) 594-7198.

Name of SEP: Clinical Sciences.

Date: April 6, 1995.

Time: 11:00 a.m.

Place: NIH, Westwood Building, Room 220, Telephone Conference.

Contact Person: Dr. Daniel McDonald, Scientific Review Administrator, 5333 Westbard Ave., Room 220, Bethesda, MD 20892, (301) 594-7301.

Name of SEP: Clinical Sciences.

Date: April 6, 1995.

Time: 12:00 noon.

Place: NIH, Westwood Building, Room 220, Telephone Conference.

Contact Person: Dr. Daniel McDonald, Scientific Review Administrator, 5333 Westbard Ave., Room 220, Bethesda, MD 20892, (301) 594-7301.

Name of SEP: Clinical Sciences.

Date: April 6, 1995.

Time: 1:00 p.m.

Place: NIH, Westwood Building, Room 220, Telephone Conference.

Contact Person: Dr. Daniel McDonald, Scientific Review Administrator, 5333 Westbard Ave., Room 220, Bethesda, MD 20892, (301) 594-7301.

The meetings will be closed in accordance with the provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the grant review cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: March 13, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, NIH.

[FR Doc. 95-6564 Filed 3-15-95; 8:45 am]

BILLING CODE 4140-01-M

Notice of Meeting of the Alternative Medicine Program Advisory Council and its Subcommittees

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meetings of the Alternative Medicine Program Advisory Council (AMPAC) and its Subcommittees on March 20, 21 and 22, 1995 at the National Institutes of Health, Building 31, 9000 Rockville Pike, Bethesda, Maryland.

In accordance with the provisions set forth in sec. 552b(c)(6), Title 5, U.S.C., the full Council will meet on March 20 in closed session in Conference Room 7, from 8:30 am to 9:30 am to discuss conflict of interest procedures, issues, and questions relating to the operation of the AMPAC and its Subcommittees. These discussions could disclose information of a personal nature where disclosure would constitute a clearly unwarranted invasion of personal privacy.

Meeting of the Subcommittees will be open to the public on March 20 at the times and locations listed below for the discussion of planning and priority of activities. Attendance by the public will be limited to space available.

Subcommittee Name: Research Subcommittee.

Place: Conference Room 6.

Time: 9:30 a.m. to 12:45 p.m.

Subcommittee Name: Information Services Subcommittee.

Place: Conference Room 6.

Time: 1:45 p.m. to 5 p.m.

Subcommittee Name: Professional Liaison Subcommittee.

Place: Conference Room 7.

Time: 1:45 p.m. to 5 p.m.

The full Council will meet in open session on March 21 from 8:30 am to 5:15 pm and on March 22 from 8:30 am to 12:30 pm in Conference Room 10. There will be a report from the Acting Director, Office of Alternative Medicine, from the chairs of the Research and Information Services Subcommittees, and the Longrange Planning Workgroup of the Strategic Planning Subcommittee, and from representatives of the two funded Centers for Alternative Medicine Research. Comments may be made by the public from 3:15 pm to 4:30 pm on March 21 and from 10:45 am to 11:15 am on March 22. Attendance by the public will be limited to space available.

Ms. Beth Clay, Committee Management Officer, Office of Alternative Medicine, NIH, 6120 Executive Boulevard, Suite 450, Rockville, MD 20892-9904, phone (301) 402-2467, fax (301) 402-4741, will furnish the meeting agenda, roster of Council members, and substantive program information upon request. Any individual who requires special assistance, such as sign language interpretation or other reasonable accommodations, should contact Ms. Clay at the above location no later than March 16, 1995.

This notice is being published less than fifteen days prior to the meeting due to difficulties encountered in finalized the agenda and the need to proceed with the meeting as scheduled to address important issues in a timely manner.

Dated: March 13, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, NIH.

[FR Doc. 95-6563 Filed 3-15-95; 8:45 am]

BILLING CODE 4140-01-M